Informazione:
Errore:
ID
15392
Descrizione
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014); ODM derived from: https://clinicaltrials.gov/show/NCT00106145
collegamento
https://clinicaltrials.gov/show/NCT00106145
Keywords
versioni (1)
- 29/05/16 29/05/16 -
Caricato su
29 maggio 2016
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Eligibility Advanced Breast Cancer NCT00106145
Eligibility Advanced Breast Cancer NCT00106145
- StudyEvent: Eligibility
Similar models
Eligibility Advanced Breast Cancer NCT00106145
- StudyEvent: Eligibility
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
age
Item
women or men greater than or equal to 18 years of age
boolean
C0001779 (UMLS CUI [1])
ecog
Item
ecog status less than or equal to 2 (a measurement to determine your ability to perform daily activities)
boolean
C1520224 (UMLS CUI [1])
solid tumor
Item
in parts i, iii, and iv, patient must have a histologically confirmed, metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist. there is no limit on the number of prior treatment regimens
boolean
C0280100 (UMLS CUI [1])
breast cancer
Item
in part ii, only breast cancer patients are eligible
boolean
C0678222 (UMLS CUI [1])
numb immunoreactivity
Item
in part v, only patients with numb negative breast cancer (i.e., tumor shows numb immunoreactivity in less than 10% of the neoplastic cells assessed) are eligible
boolean
C1417890 (UMLS CUI [1,1])
C0597879 (UMLS CUI [1,2])
C0597879 (UMLS CUI [1,2])
antineoplastic therapy
Item
patient has recovered from and is at least 2 weeks from previous antineoplastic therapy, including chemotherapy, biological therapy (including herceptin), hormonal therapy, radiotherapy, or surgery
boolean
C2346834 (UMLS CUI [1])
investigational treatment
Item
patient has had an investigational treatment in the preceding 21 days
boolean
congestive heart failure
Item
uncontrolled congestive heart failure or myocardial infarction (heart attack) within 3 months of study start
boolean
C0018802 (UMLS CUI [1])
hepatitis
Item
history of hepatitis b or c or hiv
boolean
C0019158 (UMLS CUI [1])
central nervous system metastases
Item
patient has the presence of clinically apparent central nervous system metastases or carcinomatous meningitis. patients with cns metastases who have completed a course of radiotherapy and are clinically stable in the judgment of the investigator are eligible
boolean
C0279130 (UMLS CUI [1])
second malignancy
Item
patients with "currently active" second malignancy, other than non-melanoma skin cancer, should not be enrolled. patients are not considered to have a "currently active" malignancy if they have completed therapy for prior malignancy and are considered by their physician to be at <30% risk of relapse
boolean
C0751623 (UMLS CUI [1])